Abaxis (Abaxis) Retained Earnings : $143.9 Mil (As of Mar. 2018)

View and export this data going back to 1992. Start your Free Trial

What is Abaxis Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Abaxis's retained earnings for the quarter that ended in Mar. 2018 was $143.9 Mil.

Abaxis's quarterly retained earnings increased from Sep. 2017 ($136.9 Mil) to Dec. 2017 ($137.5 Mil) and increased from Dec. 2017 ($137.5 Mil) to Mar. 2018 ($143.9 Mil).

Abaxis's annual retained earnings increased from Mar. 2016 ($109.3 Mil) to Mar. 2017 ($130.3 Mil) and increased from Mar. 2017 ($130.3 Mil) to Mar. 2018 ($143.9 Mil).

Abaxis Retained Earnings Historical Data

The historical data trend for Abaxis's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abaxis Retained Earnings Chart

Abaxis Annual Data

Trend

Mar09

Mar10

Mar11

Mar12

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Retained Earnings

Get a 7-Day Free Trial

69.32

87.64

109.30

130.30

143.87

Abaxis Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18
Retained Earnings	Get a 7-Day Free Trial															130.30	133.46	136.89	137.48	143.87

Abaxis Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Abaxis (NAS:ABAX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Abaxis (Abaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Abaxis Inc (NAS:ABAX) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.abaxis.com

Abaxis Inc manufactures point-of-care blood analysis instruments and consumables for medical and veterinary care providers. The medical segment sells Piccolo Chemistry Analyzers, which can provide results about a blood sample in 12 minutes, and related reagents to physicians, hospitals, pharmacies, and other healthcare providers. The veterinary segment generates the majority of the firm's total revenue and sells products to animal hospitals, veterinary clinics, and private research laboratories. Products in this segment include the VetScan VS2 chemistry analyzer, animal-specific reagents, and rapid tests for canine and feline diseases. The vast majority of the firm's revenue comes from North America and Europe.

Executives

Richard Bastiani	director	C/O ABAXIS INC, 3240 WHIPPLE RD, UNION CITY CA 94587
Taylor Dean Ross Jr	officer: CFO and VP of Finance	C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Clinton Severson	director, officer: CEO & Board Chairman	C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Michael D Casey	director	ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020